Navigation Links
Chemotherapy timing is key to success
Date:5/8/2014

CAMBRIDGE, Mass-- MIT researchers have devised a novel cancer treatment that destroys tumor cells by first disarming their defenses, then hitting them with a lethal dose of DNA damage.

In studies with mice, the research team showed that this one-two punch, which relies on a nanoparticle that carries two drugs and releases them at different times, dramatically shrinks lung and breast tumors. The MIT team, led by Michael Yaffe, the David H. Koch Professor in Science, and Paula Hammond, the David H. Koch Professor in Engineering, describe the findings in the May 8 online edition of Science Signaling.

"I think it's a harbinger of what nanomedicine can do for us in the future," says Hammond, who is a member of MIT's Koch Institute for Integrative Cancer Research. "We're moving from the simplest model of the nanoparticle just getting the drug in there and targeting it to having smart nanoparticles that deliver drug combinations in the way that you need to really attack the tumor."

Doctors routinely give cancer patients two or more different chemotherapy drugs in hopes that a multipronged attack will be more successful than a single drug. While many studies have identified drugs that work well together, a 2012 paper from Yaffe's lab was the first to show that the timing of drug administration can dramatically influence the outcome.

In that study, Yaffe and former MIT postdoc Michael Lee found they could weaken cancer cells by administering the drug erlotinib, which shuts down one of the pathways that promote uncontrolled tumor growth. These pretreated tumor cells were much more susceptible to treatment with a DNA-damaging drug called doxorubicin than cells given the two drugs simultaneously.

"It's like rewiring a circuit," says Yaffe, who is also a member of the Koch Institute. "When you give the first drug, the wires' connections get switched around so that the second drug works in a much more effective way."'/>"/>

Contact: Andrew Carleen
acarleen@mit.edu
617-253-1682
Massachusetts Institute of Technology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Harmless human virus may be able to boost the effects of chemotherapy
2. Nanobubbles plus chemotherapy equals single-cell cancer targeting
3. New biomarker for common lung cancer predicts responses to chemotherapy
4. Scientists uncover strategy able to dramatically reduce chemotherapys side effects
5. Neutrons help explain why antibiotics prescribed for chemotherapy cause kidney failure
6. New way to kill lymphoma without chemotherapy
7. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
8. Discovery may help prevent chemotherapy-induced anemia
9. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
10. Neuroblastoma: Autophagy protects from chemotherapy
11. Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2015)...  Acuity Market Intelligence,s latest research "The Global ... and Privacy" forecasts that between 2014 and 2020 ... downloaded to smart mobile devices by 2.2 billion ... projected to generate more than $67.9 billion in ... period.    "Biometrics is at the ...
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new ... fully hardware encapsulated fingerprint sensor and matching ... is literally off the grid, isolating fingerprint ... within the fingerprint sensor to provide ultimate ...
Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
... famed for their fallibility. Gooey glues soon lose their grip, ... feet. Geckos can cling on repeatedly to the smoothest surfaces ... the soles of their feet. Back in 2002, Kellar Autumn ... with surfaces that the reptiles ,glue, themselves on by van ...
... of ecosystems across the globe, providing water for drinking and ... life forms in rivers and streams from single-celled organisms all ... and nature itself are making it tough on rivers to ... to new research by a team of scientists including one ...
... -- Water vapor and clouds are the major contributors ... modeling study shows that the planet,s temperature ultimately depends ... The study, conducted by Andrew Lacis and colleagues at ... York, examined the nature of Earth,s greenhouse effect and ...
Cached Biology News:Humidity makes gecko feet stickier 2A river ran through it 2A river ran through it 3A river ran through it 4Carbon dioxide controls Earth's temperature 2Carbon dioxide controls Earth's temperature 3
(Date:7/30/2015)... , July 30, 2015   Aratana Therapeutics, ... therapeutics company focused on the licensing, development and ... today announced that its strategic partner VetStem Biopharma, ... confirmation study of AT-016, an adipose-derived allogeneic stem ... treatment of osteoarthritis pain in dogs. ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes ... Reported sales were $697 million compared to $701 million ... by 8%, and changes in foreign currency exchange rates ... 1%. , By business unit, organic sales growth ... in SAFC Commercial. , Reported diluted EPS was ...
(Date:7/30/2015)... New York, NY (PRWEB) , ... July 30, 2015 , ... As part of its ... raw material and technical service business units, Whitehouse Laboratories is pleased ... facility will be adjacent to the Container Center of Excellence and will be strictly dedicated ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... Process for Picoplatin -SOUTH SAN FRANCISCO, Calif., May 12 ... a biopharmaceutical company focused on innovative oncology therapies, today ... will present at the BIO International Convention on Tuesday, ... Mr. Martell will provide an overview of the ...
... HILLS, Mass., May 12 Joseph F. Finn, Jr., ... Therapeutics, Inc. ("Prospect") have been assigned to him for ... is a carbohydrate molecule designed to inhibit the activity ... a broad range of human cancers and whose over-expression ...
... Biodiesel industry leader to acquire 105 MGY of additional capacity in ... ... Ames, Iowa (Vocus) May 12, 2009 -- Renewable Energy Group® ... commercial-scale biodiesel plants. Western Iowa Energy, which operates a 30 MGY ...
Cached Biology Technology:Poniard Pharmaceuticals to Present at the 2009 BIO International Convention 2Poniard Pharmaceuticals to Present at the 2009 BIO International Convention 3Prospect Therapeutics, Inc. Assigns All Its Assets to Joseph F. Finn, Jr., C.P.A. for the Benefit of Its Creditors 2REG Signs Agreement with Three Biodiesel Plants to Consolidate 2REG Signs Agreement with Three Biodiesel Plants to Consolidate 3REG Signs Agreement with Three Biodiesel Plants to Consolidate 4REG Signs Agreement with Three Biodiesel Plants to Consolidate 5REG Signs Agreement with Three Biodiesel Plants to Consolidate 6REG Signs Agreement with Three Biodiesel Plants to Consolidate 7
... peptide-1(7-36) amide (GLP-1), C-terminal reactive. Cross-reacts ... <0.1% cross reactivity with the unamidated ... related peptides such as hGLP-2, glucagon, ... species. GLP-1 is identical in all ...
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: